Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Antibiotic | Research

A clinical prediction tool for extended-spectrum β-lactamase-producing Enterobacteriaceae urinary tract infection

Authors: Hui Liu, Suishan Qiu, Minghao Chen, Jun Lyu, Guangchao Yu, Lianfang Xue

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Prevalence of extended-spectrum beta-lactamase-producing-Enterobacteriaceae (ESBL-E) has risen in patients with urinary tract infections. The objective of this study was to determine explore the risk factors of ESBL-E infection in hospitalized patients and establish a predictive model.

Methods

This retrospective study included all patients with an Enterobacteriaceae-positive urine sample at the first affiliated hospital of Jinan university from January 2018 to December 2019. Antimicrobial susceptibility patterns of ESBL-E were analyzed, and multivariate analysis of related factors was performed. From these, a nomogram was established to predict the possibility of ESBL-E infection. Simultaneously, susceptibility testing of a broad array of carbapenem antibiotics was performed on ESBL-E cultures to explore possible alternative treatment options.

Results

Of the total 874 patients with urinary tract infections (UTIs), 272 (31.1%) were ESBL-E positive. In the predictive analysis, five variables were identified as independent risk factors for ESBL-E infection: male gender (OR = 1.607, 95% CI 1.066–2.416), older age (OR = 4.100, 95% CI 1.678–12.343), a hospital stay in preceding 3 months (OR = 1.872, 95% CI 1.141–3.067), invasive urological procedure (OR = 1.810, 95% CI 1.197–2.729), and antibiotic use within the previous 3 months (OR = 1.833, 95% CI 1.055–3.188). In multivariate analysis, the data set was divided into a training set of 611 patients and a validation set of 263 patients The model developed to predict ESBL-E infection was effective, with the AuROC of 0.650 (95% CI 0.577–0.725). Among the antibiotics tested, several showed very high effectiveness against ESBL-E: amikacin (85.7%), carbapenems (83.8%), tigecycline (97.1%) and polymyxin (98.2%).

Conclusions

The nomogram is useful for estimating a UTI patient’s likelihood of infection with ESBL-E. It could improve clinical decision making and enable more efficient empirical treatment. Empirical treatment may be informed by the results of the antibiotic susceptibility testing.
Literature
1.
go back to reference Lim MSS, Wong PL, Sulaiman H, Atiya N, Shunmugam HR, Liew SM. Clinical prediction models for ESBL-Enterobacteriaceae colonization or infection: a systematic review. J Hospital Infect. 2019;102(1):8–16.CrossRef Lim MSS, Wong PL, Sulaiman H, Atiya N, Shunmugam HR, Liew SM. Clinical prediction models for ESBL-Enterobacteriaceae colonization or infection: a systematic review. J Hospital Infect. 2019;102(1):8–16.CrossRef
2.
go back to reference Xiao Y, Hang Y, Chen Y, Fang X, Cao X, Hu X, et al. A retrospective analysis of risk factors and patient outcomes of bloodstream infection with extended-spectrum β-lactamase-producing Escherichia coli in a Chinese Tertiary Hospital. Infect Drug Resist. 2020;13:4289–96.CrossRef Xiao Y, Hang Y, Chen Y, Fang X, Cao X, Hu X, et al. A retrospective analysis of risk factors and patient outcomes of bloodstream infection with extended-spectrum β-lactamase-producing Escherichia coli in a Chinese Tertiary Hospital. Infect Drug Resist. 2020;13:4289–96.CrossRef
3.
go back to reference Martinez-Valencia AJ, Gomez MB, Montanez AA, Garcia K, Sanchez PR, Jimenez CL, et al. Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections. Bmc Infect Dis. 2020;20(1):558.CrossRef Martinez-Valencia AJ, Gomez MB, Montanez AA, Garcia K, Sanchez PR, Jimenez CL, et al. Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections. Bmc Infect Dis. 2020;20(1):558.CrossRef
4.
go back to reference Kim M, Song KH, Kim CJ, Choe PG, Park WB, Bang JH, et al. Clinical prediction score for community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. J Korean Med Sci. 2019;34(14):e116.CrossRef Kim M, Song KH, Kim CJ, Choe PG, Park WB, Bang JH, et al. Clinical prediction score for community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. J Korean Med Sci. 2019;34(14):e116.CrossRef
5.
go back to reference Yi-Te C, Shigemura K, Nishimoto K, Yamada N, Kitagawa K, Sung SY, et al. Urinary tract infection pathogens and antimicrobial susceptibilities in Kobe, Japan and Taipei, Taiwan: an international analysis. J Int Med Res. 2020;48(2):1219667378.CrossRef Yi-Te C, Shigemura K, Nishimoto K, Yamada N, Kitagawa K, Sung SY, et al. Urinary tract infection pathogens and antimicrobial susceptibilities in Kobe, Japan and Taipei, Taiwan: an international analysis. J Int Med Res. 2020;48(2):1219667378.CrossRef
6.
go back to reference Xiao T, Wu Z, Shi Q, Zhang X, Zhou Y, Yu X, et al. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections. J Glob Antimicrob Resist. 2019;17:147–56.CrossRef Xiao T, Wu Z, Shi Q, Zhang X, Zhou Y, Yu X, et al. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections. J Glob Antimicrob Resist. 2019;17:147–56.CrossRef
7.
go back to reference Vachvanichsanong P, McNeil EB, Dissaneewate P. Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections. Epidemiol Infect. 2020;149:e12.CrossRef Vachvanichsanong P, McNeil EB, Dissaneewate P. Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections. Epidemiol Infect. 2020;149:e12.CrossRef
8.
go back to reference Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016;22(Suppl 1):S9-14.CrossRef Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016;22(Suppl 1):S9-14.CrossRef
9.
go back to reference Raphael E, Glymour MM, Chambers HF. Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. Antimicrob Resist Infect Control. 2021;10:118.CrossRef Raphael E, Glymour MM, Chambers HF. Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. Antimicrob Resist Infect Control. 2021;10:118.CrossRef
10.
go back to reference Lee H, Han SB, Kim JH, Kang S, Durey A. Risk factors of urinary tract infection caused by extended spectrum β-lactamase-producing Escherichia coli in emergency department. Am J Emerg Med. 2018;36(9):1608–12.CrossRef Lee H, Han SB, Kim JH, Kang S, Durey A. Risk factors of urinary tract infection caused by extended spectrum β-lactamase-producing Escherichia coli in emergency department. Am J Emerg Med. 2018;36(9):1608–12.CrossRef
11.
go back to reference Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20(Suppl 1):1–55.CrossRef Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20(Suppl 1):1–55.CrossRef
12.
go back to reference Xie J, Peters BM, Li B, Li L, Yu G, Xu Z, et al. Clinical features and antimicrobial resistance profiles of important Enterobacteriaceae pathogens in Guangzhou representative of Southern China, 2001–2015. Microb Pathogenesis. 2017;107:206–11.CrossRef Xie J, Peters BM, Li B, Li L, Yu G, Xu Z, et al. Clinical features and antimicrobial resistance profiles of important Enterobacteriaceae pathogens in Guangzhou representative of Southern China, 2001–2015. Microb Pathogenesis. 2017;107:206–11.CrossRef
13.
go back to reference Tenney J, Hudson N, Alnifaidy H, Li J, Fung KH. Risk factors for aquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. Saudi Pharm J. 2018;26(5):678–84.CrossRef Tenney J, Hudson N, Alnifaidy H, Li J, Fung KH. Risk factors for aquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. Saudi Pharm J. 2018;26(5):678–84.CrossRef
14.
go back to reference Gomila A, Shaw E, Carratala J, Leibovici L, Tebe C, Wiegand I, et al. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections. Antimicrob Resist Infect Control. 2018;7:111.CrossRef Gomila A, Shaw E, Carratala J, Leibovici L, Tebe C, Wiegand I, et al. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections. Antimicrob Resist Infect Control. 2018;7:111.CrossRef
15.
go back to reference Goossens H. MYSTIC SGE. MYSTIC program: summary of European data from 1997 to 2000. Diagn Micr Infec Dis. 2001;41(4):183–9.CrossRef Goossens H. MYSTIC SGE. MYSTIC program: summary of European data from 1997 to 2000. Diagn Micr Infec Dis. 2001;41(4):183–9.CrossRef
16.
go back to reference Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. World J Urol. 2016;34(7):1031–7.CrossRef Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. World J Urol. 2016;34(7):1031–7.CrossRef
17.
go back to reference Albaramki JH, Abdelghani T, Dalaeen A, Khdair AF, Alassaf A, Odeh R, et al. Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria: risk factors and antibiotic resistance. Pediatr Int. 2019;61(11):1127–32.CrossRef Albaramki JH, Abdelghani T, Dalaeen A, Khdair AF, Alassaf A, Odeh R, et al. Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria: risk factors and antibiotic resistance. Pediatr Int. 2019;61(11):1127–32.CrossRef
18.
go back to reference Fernando MM, Luke WA, Miththinda JK, Wickramasinghe RD, Sebastiampillai BS, Gunathilake MP, et al. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study. Bmc Infect Dis. 2017;17(1):138.CrossRef Fernando MM, Luke WA, Miththinda JK, Wickramasinghe RD, Sebastiampillai BS, Gunathilake MP, et al. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study. Bmc Infect Dis. 2017;17(1):138.CrossRef
19.
go back to reference Boyer A, Couallier V, Clouzeau B, Lasheras A, M’Zali F, Kann M, et al. Control of extended-spectrum beta-lactamase-producing Enterobacteriaceae nosocomial acquisition in an intensive care unit: a time series regression analysis. Am J Infect Control. 2015;43(12):1296–301.CrossRef Boyer A, Couallier V, Clouzeau B, Lasheras A, M’Zali F, Kann M, et al. Control of extended-spectrum beta-lactamase-producing Enterobacteriaceae nosocomial acquisition in an intensive care unit: a time series regression analysis. Am J Infect Control. 2015;43(12):1296–301.CrossRef
20.
go back to reference Golzarri MF, Silva-Sanchez J, Cornejo-Juarez P, Barrios-Camacho H, Chora-Hernandez LD, Velazquez-Acosta C, et al. Colonization by fecal extended-spectrum beta-lactamase-producing Enterobacteriaceae and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery. Am J Infect Control. 2019;47(8):916–21.CrossRef Golzarri MF, Silva-Sanchez J, Cornejo-Juarez P, Barrios-Camacho H, Chora-Hernandez LD, Velazquez-Acosta C, et al. Colonization by fecal extended-spectrum beta-lactamase-producing Enterobacteriaceae and surgical site infections in patients with cancer undergoing gastrointestinal and gynecologic surgery. Am J Infect Control. 2019;47(8):916–21.CrossRef
22.
go back to reference Garcia-Tello A, Gimbernat H, Redondo C, Meilan E, Arana DM, Cacho J, et al. Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram. Scand J Urol. 2018;52(1):70–5.CrossRef Garcia-Tello A, Gimbernat H, Redondo C, Meilan E, Arana DM, Cacho J, et al. Prediction of infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: development of a clinical decision-making nomogram. Scand J Urol. 2018;52(1):70–5.CrossRef
24.
go back to reference Liao K, Chen Y, Wang M, Guo P, Yang Q, Ni Y, et al. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae causing intra-abdominal infections from 9 tertiary hospitals in China. Diagn Microbiol Infect Dis. 2017;87(1):45–8.CrossRef Liao K, Chen Y, Wang M, Guo P, Yang Q, Ni Y, et al. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae causing intra-abdominal infections from 9 tertiary hospitals in China. Diagn Microbiol Infect Dis. 2017;87(1):45–8.CrossRef
25.
go back to reference Espinar MJ, Miranda IM, Costa-de-Oliveira S, Rocha R, Rodrigues AG, Pina-Vaz C. Urinary tract infections in kidney transplant patients due to Escherichia coli and Klebsiella pneumoniae-producing extended-spectrum beta-lactamases: risk factors and molecular epidemiology. Plos One. 2015;10(8):e134737.CrossRef Espinar MJ, Miranda IM, Costa-de-Oliveira S, Rocha R, Rodrigues AG, Pina-Vaz C. Urinary tract infections in kidney transplant patients due to Escherichia coli and Klebsiella pneumoniae-producing extended-spectrum beta-lactamases: risk factors and molecular epidemiology. Plos One. 2015;10(8):e134737.CrossRef
26.
go back to reference Kwon KT, Kim B, Ryu S, Wie S, Kim J, Jo H, et al. Changes in clinical characteristics of community-acquired acute pyelonephritis and antimicrobial resistance of uropathogenic Escherichia coli in South Korea in the Past Decade. Antibiotics (Basel). 2020;9(9):1. Kwon KT, Kim B, Ryu S, Wie S, Kim J, Jo H, et al. Changes in clinical characteristics of community-acquired acute pyelonephritis and antimicrobial resistance of uropathogenic Escherichia coli in South Korea in the Past Decade. Antibiotics (Basel). 2020;9(9):1.
27.
go back to reference Yu Y, Shen H, Zhu C, Guo R, Gao Y, Lu L. Infections caused by extended-spectrum beta-lactamase producing Escherichia Coli in systemic lupus erythematosus patients: prevalence, risk factors, and predictive model. Biomed Res Int. 2018;2018:8296720.PubMedPubMedCentral Yu Y, Shen H, Zhu C, Guo R, Gao Y, Lu L. Infections caused by extended-spectrum beta-lactamase producing Escherichia Coli in systemic lupus erythematosus patients: prevalence, risk factors, and predictive model. Biomed Res Int. 2018;2018:8296720.PubMedPubMedCentral
28.
go back to reference Sader HS, Flamm RK, Jones RN. Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009–2011). J Chemotherapy (Florence). 2014;26(3):133–8.CrossRef Sader HS, Flamm RK, Jones RN. Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009–2011). J Chemotherapy (Florence). 2014;26(3):133–8.CrossRef
29.
go back to reference Wu G, Abraham T, Saad N. Role of tigecycline for the treatment of urinary tract infections. J Pharm Technol. 2014;30(3):87–92.CrossRef Wu G, Abraham T, Saad N. Role of tigecycline for the treatment of urinary tract infections. J Pharm Technol. 2014;30(3):87–92.CrossRef
Metadata
Title
A clinical prediction tool for extended-spectrum β-lactamase-producing Enterobacteriaceae urinary tract infection
Authors
Hui Liu
Suishan Qiu
Minghao Chen
Jun Lyu
Guangchao Yu
Lianfang Xue
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07040-y

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue